Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
18.92
-1.04 (-5.21%)
At close: Feb 13, 2026, 4:00 PM EST
19.27
+0.35 (1.85%)
After-hours: Feb 13, 2026, 7:16 PM EST
Arcus Biosciences Employees
Arcus Biosciences had 627 employees as of December 31, 2024. The number of employees increased by 50 or 8.67% compared to the previous year.
Employees
627
Change (1Y)
50
Growth (1Y)
8.67%
Revenue / Employee
$382,775
Profits / Employee
-$543,860
Market Cap
2.34B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 627 | 50 | 8.67% |
| Dec 31, 2023 | 577 | 77 | 15.40% |
| Dec 31, 2022 | 500 | 134 | 36.61% |
| Dec 31, 2021 | 366 | 130 | 55.08% |
| Dec 31, 2020 | 236 | 97 | 69.78% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Apellis Pharmaceuticals | 710 |
| Adaptive Biotechnologies | 619 |
| Beam Therapeutics | 510 |
| Travere Therapeutics | 385 |
| Tarsus Pharmaceuticals | 323 |
| Dyne Therapeutics | 240 |
| Immunome | 168 |
| Viridian Therapeutics | 143 |
RCUS News
- 3 days ago - Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates - Business Wire
- 19 days ago - Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
- 4 weeks ago - Arcus Biosciences, Inc. (RCUS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs - Business Wire
- 2 months ago - Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - Arcus Biosciences: Casdatifan Takes Center Stage After STAR-221 - Seeking Alpha
- 2 months ago - Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug - Benzinga
- 2 months ago - Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio - Business Wire